Compounded Avastin Recall Good News for Regeneron
The FDA raised another safety flag over the continued off-label use of Avastin Wednesday when it issued a MedWatch alerting physicians of a recall of the compounded cancer drug intended as an unapproved treatment for wet age-related macular degeneration (AMD).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter